Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
Dunlop W, van Keep M, Elroy P, Perez ID, Ouwens MJNM, Sarbajna T, Zhang Y, Greystoke A.
Dunlop W, et al.
Pharmacoecon Open. 2022 Mar;6(2):241-252. doi: 10.1007/s41669-021-00301-7. Epub 2021 Sep 16.
Pharmacoecon Open. 2022.
PMID: 34532842
Free PMC article.
As patients in the study at the time of the initial submission to NICE were only followed for approximately 2 years, the long-term survival benefit that could be achieved with durvalumab was uncertain. ...Here, we demonstrate that the original cost-effectiveness model accu …
As patients in the study at the time of the initial submission to NICE were only followed for approximately 2 years, the long-term su …